drugset / Trial / NCT00565266

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

NCT00565266 ↗

RandomizedCrossoverQuadruple-blindTreatment

Summary

Typically, people with asthma are initially prescribed a low dose of inhaled corticosteroid (ICS) medication to control asthma symptoms. If a low dose of ICS is ineffective at controlling symptoms, the addition of a second controller medication is recommended. This study will examine the effectiveness of the medication tiotropium bromide combined with a low dose of ICS at maintaining asthma control in people with moderately severe asthma.

Timeline

Start
2008-05
Primary completion
2010-05
Completion
2010-05

Outcome

Met primary endpoint

paper The use of tiotropium resulted in a superior primary outcome PMID 20979471 ↗

paper as assessed by measuring the morning peak expiratory flow (PEF), with a mean difference of 25.8 liters per minute (P<0.001) PMID 20979471 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 18 ug Inhaled
Subject beclomethasone dipropionate Other / unclassified 80 ug Inhaled
Subject beclomethasone dipropionate Other / unclassified 160 ug Inhaled
Subject salmeterol xinafoate Unknown 50 ug Inhaled

Indications